HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on BioXcel Therapeutics but lowered the price target from $7 to $5.
October 21, 2024 | 10:20 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained a Buy rating on BioXcel Therapeutics but lowered the price target from $7 to $5, indicating a more cautious outlook.
The maintenance of a Buy rating suggests continued confidence in BioXcel Therapeutics, but the lowered price target reflects a more cautious outlook on its short-term performance. This mixed signal may result in neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100